Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Recursion Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 2 insiders, $435.0K in total
- Insiders trading
- 2
- Net value
- −$435.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Recursion Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Taylor Ben R | Chief Financial Officer | 1,071,462 | Sep 16, 2026 | 12 |
| Khan Najat | CEO and President | 2,072,890 | Sep 10, 2026 | 10 |
| Borgeson Blake | Director | 6,158,287 | Sep 2, 2026 | 11 |
| Hallett David | Chief Scientific Officer | 1,043,837 | Aug 18, 2026 | 4 |
| Dar Zavain | Director | 240,764 | Jul 2, 2026 | 5 |
| Li Dean Y | Director | 1,473,329 | Jul 2, 2026 | 5 |
| Hershberg Robert | Director | 162,156 | Jun 22, 2026 | 1 |
| Sun Elaine D | Director | 135,981 | Jun 22, 2026 | 1 |
| Michor Franziska | Director | 215,477 | Jun 22, 2026 | 1 |
| Bumpus Namandje | Director | 127,632 | Jun 22, 2026 | 2 |
| Gibson Christopher | Director | 883,735 | Jun 5, 2026 | 18 |
| Mauro David J | Chief Medical Officer | 225,429 | Nov 19, 2024 | 0 |
| Secora Michael | Chief Financial Officer | 1,487,694 | Nov 19, 2024 | 0 |
| Larson Tina Marriott | President and COO | 506,852 | Nov 19, 2024 | 0 |
| Burrell Terry-Ann | Director | 71,254 | Jul 3, 2024 | 0 |
| Chavez R. Martin | Director | 60,078 | Apr 3, 2024 | 0 |
| Virani Shafique | Chief Business Officer | 136,748 | Jan 18, 2024 | 0 |
| Bogue Zachary | Director, 10% Owner | 9,378 | Jul 6, 2023 | 0 |
| Mamoura Diversified Global Holding PJSC | 10% Owner | 12,985,927Indirect | Mar 3, 2023 | 0 |
| Mubadala Investment Co PJSC | 10% Owner | 12,985,927Indirect | Mar 3, 2023 | 0 |
| Doyle Ramona | Chief Medical Officer | 121,110 | May 18, 2022 | 0 |
| Lux Ventures IV, L.P. | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Lux Venture Partners IV, LLC | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Hebert Peter | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Lux Co-Invest Partners, LLC | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Lux Co-Invest Opportunities, L.P. | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Wolfe Josh | Other: Former 10% Owner | 13,021,519 | Dec 9, 2021 | 0 |
| Mic Capital Partners (Public) (US) Im, LLC | Other: See remarks | – | Nov 3, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.03 | −$173.5K | −0.1%7.65M after | |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.75 | −$180.5K | −0.1%7.66M after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Larson Tina MarriottPresident and COO | SSaleClass A Common Stock | −2.50K | $18.74 | −$46.9K | −5.0%47.5K after | 3 lots |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −200 | $20.01 | −$4.00K | −0.8%23.5K after | |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −100 | $20.02 | −$2.00K | −0.4%23.5K after | |
| Dec 10, 2021 (view filing) | Dec 8-9 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −11.8K | $20.14 | −$236.6K | −33.4%23.5K after | 3 lots |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass B Common Stock | −16.7K | $20.48 | −$341.3K | −0.2%8.20M after | 2 lots |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass B Common Stock | −3.13K | $20.51 | −$64.1K | −2.1%146.9K after | 2 lots |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $20.31 | −$195.5K | −0.1%7.67M after | 3 lots |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Li Dean YDirector | SSaleClass A Common Stock | −15.9K | $20.48 | −$325.6K | −1.2%1.31M after | 2 lots |
| Dec 9, 2021 (view filing) | Nov 17-19 | 22 days | Li Dean YDirector | SSaleClass A Common Stock | −19.1K | $20.15 | −$384.9K | −1.4%1.33M after | Amended2 lots |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Larson Tina MarriottPresident and COO | SSaleClass A Common Stock | −2.50K | $18.92 | −$47.3K | −4.8%50.0K after | 2 lots |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.91 | −$182.0K | −0.1%7.68M after | 2 lots |